BVX.L

BiVictriX Therapeutics plc
BiVictriX Therapcts. - Director Dealing
2nd September 2024, 07:50
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5009C
BiVictriX Therapeutics PLC
02 September 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Director Dealing

 

Alderley Park,  2 September 2024 BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces the following dealing in the  Company's ordinary shares of 1 pence each ("Ordinary Shares").

 

On 30 August 2024, Mr Robert Hawkins, a Non-Executive Director, carried out a 'Bed and ISA' transfer of20,000 Ordinary Shares from his ISA account into a share dealing account (the "Transfer"). The shares were sold for 7.26 pence per Ordinary Shares and immediately repurchased at 7.92 pence per Ordinary Share.

 

Following the Transfer, Robert Hawkins remains beneficially interested in 325,000 Ordinary Shares which equates to 0.39 per cent. of the Company's total issued share capital.

 

ENDS

 

BiVictriX Therapeutics plc

Tiffany Thorn, Chief Executive Officer

Michael Kauffman, Non-Executive Chairman

 

 Email: info@bivictrix.com

 

SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)

 

 

Tel: +44 (0) 20 3470 0470

 

Panmure Liberum Limited (Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden

 

 

Tel: +44 (0) 20 3100 2000

 

ICR Consilium      

Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe

 

 

Tel: +44 (0) 20 3709 5700

Email: Bivictrix@consilium-comms.com

 

 

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

 

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Hawkins  

2. 

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BiVictriX Therapeutics plc

b)

LEI

213800ZI85IZNA6N3L53

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each

GB00BNXH3K91

Identification code


b)

Nature of the transaction

(i)            Sale of 20,000 Ordinary Shares from ISA account

(ii)           Purchase of 20,000 Ordinary Shares from share dealing account

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

(i)            7.26 pence

(ii)           7.92 pence

 

20,000

20,000

 

 

d)

Aggregated information:

-  Aggregated volume

-  Price

 N/A single transaction

e)

Date of the transaction

30 August 2024

f)

Place of the transaction

AIM, London Stock Exchange  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDZGGLNZLGDZG]]>
TwitterFacebookLinkedIn